Jefferies Initiates Coverage On Terns Pharma with Buy Rating, Announces Price Target of $18
Portfolio Pulse from richadhand@benzinga.com
Jefferies analyst Akash Tewari initiates coverage on Terns Pharma (NASDAQ:TERN) with a Buy rating and announces a price target of $18.
June 07, 2023 | 9:24 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies analyst Akash Tewari initiates coverage on Terns Pharma with a Buy rating and a price target of $18.
The initiation of coverage by Jefferies with a Buy rating and a price target of $18 indicates a positive outlook for Terns Pharma. This news is likely to attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100